Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeoStem Oncology LLC

Division of Caladrius Biosciences Inc.
www.californiastemcell.com

Latest From NeoStem Oncology LLC

Deals Shaping The Medical Industry, June 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.

BioPharmaceutical Consumer

California Stem Cell Inc.

California Stem Cell Inc.'s founder, Hans S. Keirstead, PhD, is well known in stem cell circles as the developer of processes that can produce extremely pure cell lines from human embryonic stem cells. As such, the start-up is uniquely situated. Not only does it produce over 95% pure populations of several cell types for use in research, but the firm also has proprietary reagents it sells to pharma and biotech firms. And it is building its own therapeutic pipeline: CSC is poised to file an IND for an hESC-derived therapy to treat type 1 infantile spinal muscular atrophy, the largest genetic killer of children under the age of two.
BioPharmaceutical

New Stem Cell Therapies

Recent research advances and relaxation of government restrictions have opened the stem cell field to product possibilities. Companies developing these potentially revolutionary products must also come up with workable business models. In this issue we profile five emerging contenders: Amorcyte, California Stem Cell, Cardio3 BioSciences, CellDesign and Fate Therapeutics.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • California Stem Cell Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Caladrius Biosciences Inc.
  • Senior Management
  • Hans S Keirstead , PhD, Pres. & CEO
    Jason Livingston, CFO
    Chris N Airriess , PhD, Chief Dev. Officer
    Robert O Dillman, MD, CMO
    Michael McClurg, VP, Bus. Dev.
  • Contact Info
  • NeoStem Oncology LLC
    Phone: (949) 725-1750
    18301 Von Karman Ave.
    Ste. 130
    Irvine, CA 92612
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register